Neoplastic pericarditis

Article written and reviewed by Dr Luca Moretti

Neoplastic pericarditis refers to involvement of the pericardium by a neoplasm, usually secondary and only much more rarely primary. The picture may include infiltration of the pericardial layers, nodules, thickening, effusion, and filling abnormalities. Painful inflammation is not mandatory: in many patients the predominant manifestation is a malignant effusion, sometimes with tamponade, while the term pericarditis is used in a broader clinical sense.

The fundamental distinction is between neoplastic infiltration and effusion in a person with cancer. Radiotherapy, drugs, immunotherapy, infections, renal failure, cardiac dysfunction, and hypoalbuminemia may produce fluid without tumor invasion of the pericardium. Lymphatic obstruction from mediastinal disease may also contribute to accumulation without demonstrable neoplastic cells in the sac. Correct attribution changes staging, prognosis, and treatment choice.

The pathway has three connected goals: recognizing and treating hemodynamic compromise, demonstrating the nature of the process, and preventing reaccumulation while addressing the oncologic disease. Cytology and, in selected cases, biopsy complement imaging. Decisions must consider histologic type, treatment sensitivity, general condition, and patient goals, avoiding both disproportionate procedures and automatic abandonment of interventions that can improve symptoms and therapeutic options.

Etiology, routes of spread, and diagnoses to distinguish

Secondary involvement is much more common than primary pericardial tumors. Lung and breast carcinoma, lymphomas, melanoma, and other neoplasms may reach the sac by contiguity, lymphatic spread, or the hematogenous route. The observed distribution varies with epidemiology and the oncologic population. A thoracic tumor has different anatomic possibilities from a distant neoplasm, but no primary site automatically makes every effusion malignant. Etiologic proof must remain distinct from epidemiologic plausibility.

Direct invasion may begin from pulmonary, mediastinal, or other contiguous masses. Lymphatic spread may involve the pericardium or obstruct drainage through infiltrated lymph nodes. These mechanisms may coexist with hematogenous metastases. The practical consequence is that negative cytology does not exclude every relationship between the tumor and the collection, but neither does it prove occult metastasis: infiltration, obstruction, and non-neoplastic causes must be distinguished because they do not have identical biologic or staging implications.

Lymphomas may involve the pericardium as part of systemic disease or, more rarely, with predominantly cardiac localization. Some hematolymphoid neoplasms present through effusions and require dedicated cellular characterization. Human herpesvirus 8-associated primary effusion lymphoma represents a particular setting, distinct from a generic lymphocytic effusion. Diagnosis depends on morphology, immunophenotype, and relevant investigations, not merely on a predominance of lymphocytes in the fluid.

Among primary tumors, pericardial mesothelioma is rare and may present with recurrent effusion, thickening, or constrictive physiology. Sarcomas and other masses require a specialist pathologic pathway. The absence of an identified extracardiac neoplasm does not permit immediate classification of the process as primary: a reasoned search for the site of origin must be completed. Resectability also depends on relationships with the myocardium, coronary arteries, and great vessels, not only on lesion size.

Oncologic toxicity is an important alternative diagnosis. Radiation-induced pericarditis may appear long after treatment, while various drugs and immune checkpoint inhibitors may produce serositis or other cardiac injury. During immunotherapy, progression, inflammatory response, and toxicity may coexist. A temporal relationship is a clue, not proof; stopping an effective therapy or administering immunosuppression requires attribution to be as accurate as possible.

Comorbidities complete the picture: opportunistic infections, cardiac or renal failure, low albumin, procedures, and bleeding from antithrombotic therapy may cause or amplify the effusion. In an immunocompromised patient, fever and fluid should also prompt consideration of tuberculosis and mycoses according to exposures. The oncologic diagnosis should not become an exclusive explanation that prevents recognition of a treatable complication. Sometimes multiple mechanisms are simultaneously responsible and require parallel interventions.

Pathogenesis, pathology, and pathophysiology

Infiltration of the pericardial layers alters vascular integrity and permeability, stimulates exudation, and may produce nodules or diffuse thickening. Small-vessel injury contributes to the frequently observed hemorrhagic component, but bloody fluid is not specific for tumor. Lymphatic obstruction reduces reabsorption and may maintain accumulation even when inflammation is modest. The final appearance of the effusion depends on the balance of these processes, growth rate, and treatments received.

Tumor distribution may be irregular. A limited biopsy may sample a reactive area while other regions are infiltrated; conversely, shed cells may be present in the fluid without an easily identifiable macroscopic lesion. This heterogeneity explains the complementarity of cytology, tissue, and imaging. A negative result must be interpreted in light of the sample obtained and the clinical question, without assigning absolute exclusionary power to any single method.

Progressive effusion may initially be tolerated because the sac expands. When compliance reserve is exhausted, relatively small increments may rapidly raise pressure and impair filling. Total volume therefore does not define urgency by itself. A large chronic collection may be stable, whereas a more rapidly accumulating one may cause tamponade with a smaller amount. Time course and hemodynamic signs are essential for choosing when to drain.

Tamponade reduces effective venous return and cardiac output, with compensatory tachycardia and vasoconstriction. Concomitant dehydration, sepsis, anemia, or myocardial dysfunction modifies the clinical expression. Loculations after procedures or treatments may cause regional compression that is less recognizable than a circumferential collection. Pharmacologic support may temporarily sustain perfusion but does not remove the external obstruction. An advanced cancer diagnosis does not alter this physiologic principle, although it influences shared decisions about goals of care.

Fibrous infiltration and organization of the process may produce constrictive or effusive-constrictive constraint. In these cases, drainage removes the fluid but may leave congestion because of reduced distensibility of the pericardial layers. Previous radiotherapy may add myocardial, valvular, and vascular injury, making attribution of residual symptoms complex. Persistent dyspnea after pericardiocentesis therefore requires functional assessment rather than automatically assuming that the effusion has re-formed.

Systemic impairment from congestion and reduced output may worsen renal function, liver function, and the ability to tolerate oncologic therapies. Drainage may provide a benefit beyond respiratory relief by allowing stabilization useful for further treatment. Not all limitations are reversible, however: cachexia, lung disease, embolism, and tumor progression may continue to shape the clinical picture. Expected benefit should be related to the mechanisms that are actually correctable, not to a generic promise of global recovery.

Clinical manifestations and assessment of suspicion

Dyspnea is a common presentation and may be accompanied by orthopnea, chest pressure, cough, or reduced functional capacity. Typical pleuritic pain of pericarditis may be absent. An effusion may be discovered incidentally during staging or cancer follow-up before recognizable symptoms develop. Lack of pain does not indicate benign disease, just as the presence of pain does not prove invasion: both findings must be integrated with imaging, course, and differential diagnosis.

In a patient without a cancer diagnosis, a recurrent course or subacute course, a large effusion, incomplete response to empiric therapy, and systemic symptoms may justify investigation for neoplasia. None of these findings is specific; tuberculosis and other causes may present similarly. Investigation should be guided by history, examination, and imaging, avoiding both indiscriminate tumor-marker panels and delay when suspicious anatomic findings emerge.

The oncologic history includes histologic type, known sites, disease status, and treatments received with their dates. Time since radiotherapy, initiation of immunotherapy, and use of drugs potentially associated with serositis help define alternatives. Known extracardiac progression increases the plausibility of infiltration but does not replace confirmation. Conversely, a good tumor response does not completely exclude a neoplastic pericardial complication or a new independent cause.

Signs of tamponade include tachycardia, jugular venous distention, pulsus paradoxus, hypotension, and hypoperfusion, with variability related to the rate of accumulation. Muffled heart sounds and electrical alternans may occur but are not required for diagnosis. Blood pressure may remain preserved during compensated stages. Rapidly worsening dyspnea, syncope, or reduced urine output requires urgent assessment even if the patient had been considered stable at a recent radiologic follow-up.

The general examination looks for lymph nodes, pleural signs, congestion, skin lesions, and findings that may suggest an accessible biopsy site. Concomitant infection, thromboembolism, and cardiac dysfunction must be assessed. Lower-limb edema may result from venous obstruction, hypoalbuminemia, or pericardial disease; a single sign cannot establish its cause. Selection of the most useful investigations arises from the overall distribution of findings, not merely from the presence of fluid around the heart.

Functional assessment includes independence, performance status, symptom burden, and patient expectations. These elements guide the mode of intervention without replacing hemodynamic diagnosis. A frail patient may obtain substantial relief from a minimally invasive procedure, whereas a more demanding operation requires proportionate expected benefit. Oncologic prognosis should be discussed with the treating team rather than inferred solely from the word malignant or survival medians from heterogeneous case series.

Imaging, cytology, and pathologic confirmation

Echocardiography defines the distribution of the collection, chamber collapse, respiratory flow changes, and ventricular function. It may show masses or thickening, but an examination without visible nodules does not exclude infiltration. Chest CT clarifies relationships with the lung, mediastinum, and lymph nodes and may identify a possible origin. Magnetic resonance contributes to tissue characterization and assessment of myocardial infiltration or constrictive physiology in stable patients without replacing decompression when necessary.

PET using a tracer appropriate to the neoplasm may contribute to staging and selection of a biopsy site, but pericardial metabolic uptake does not always distinguish tumor from inflammation. Even findings suggestive of malignancy require correlation. The purpose of imaging is to define anatomy, extent, and consequences, not to assign a histologic type by itself. When a safer and more informative extracardiac lesion is available, obtaining the tissue needed to characterize disease from that site may be preferable.

Pericardial cytology is fundamental when fluid is drained for clinical or diagnostic indications. An adequate sample, properly processed and accompanied by oncologic information, increases the chance of recognizing malignant cells. Cytologic preparations and cell block allow additional studies. Yield varies with tumor, cellularity, therapies, and method; the proportion of positive samples among all effusions in cancer patients does not equal test sensitivity in truly infiltrated effusions.

Immunocytochemistry may help distinguish epithelial, mesothelial, and hematolymphoid cells and guide the site of origin using appropriate panels. No marker should be interpreted in isolation, especially in reactive cells or scant samples. When lymphoma is suspected, flow cytometry and hematopathology studies should be arranged before sampling because fixation and storage may affect feasibility. The result should allow clinically useful classification rather than merely describing generic atypia.

Pericardial biopsy may be indicated if suspicion persists despite negative cytology, accessible thickening or nodules are present, or a surgical procedure is already necessary. Targeted samples may be more informative than small random fragments in irregularly distributed disease. A negative biopsy does not exclude all infiltration and must be interpreted in relation to material quality and sampling site. Cytology and histology are complementary; tissue should not be assumed to be always superior to fluid in every situation.

Hemorrhagic fluid, high protein concentration, or some tumor markers may support suspicion but do not replace cellular demonstration. Microbiologic investigations should be performed if the context requires them because infection may coexist. The diagnostic conclusion should distinguish proven malignancy, probable neoplastic relationship, and effusion of another origin. This precision is crucial when the result changes cancer stage or leads to interruption of a therapy that might still be effective.

Staging and definition of the oncologic strategy

Pericardial confirmation must be integrated into the tumor-specific staging system. The significance of the site depends on histologic type and the relevant classification; there is no single stage applicable to every tumor with an effusion. In lung carcinoma, for example, a malignant effusion has different implications from a clearly non-neoplastic collection. Documentation should specify the basis for attribution, avoiding automatic prognostic reclassification solely because fluid is present.

Biologic characterization may require immunophenotyping and molecular analyses relevant to therapy. Pericardial material may be a resource if quantity and quality are sufficient and the laboratory confirms its suitability. A result unobtainable from that specimen may require another site without multiplying unnecessary procedures. The priority is to obtain information that concretely changes treatment, taking into account what is already known from the primary tumor or other sites.

Study of local extent assesses myocardial invasion, involvement of the great vessels, and compression of adjacent structures. An infiltrative mass is not equivalent to a free effusion that can be controlled with a catheter. In rare primary tumors, assessment of resectability requires specific cardiac surgical and oncologic expertise. Incomplete resection, palliative intervention, and surgery with radical intent have different goals and should be described as such, without assuming that pericardiectomy is always curative.

In a patient receiving immunotherapy, attribution must consider immune-mediated toxicity, progression, and a possible inflammatory response associated with the disease. The presence of malignant cells proves tumor involvement but may not by itself explain the entire temporal course. Troponin, ECG, and ventricular function help investigate associated myocarditis, which radically changes urgency and management. The decision to stop or resume oncologic treatment requires multidisciplinary discussion and does not follow from a single echocardiographic finding.

Assessment of procedural risk includes platelet count, coagulation, anticoagulants, infection, respiratory status, and anatomy. Cytopenias and frailty may require corrective measures or a specialist setting, but in tamponade they must not lead to dangerous delay while waiting for ideal values. Procedure-related risks must be weighed against those of untreated compression. The possibility of obtaining diagnosis and relief at the same time is important when choosing access and drainage modality.

Shared goals may include continuation of an effective therapy, prevention of new hospitalizations, or primarily symptom relief. These goals change the balance among prolonged catheter drainage, a window, and more invasive procedures. Updated oncologic assessment is essential: treatment-sensitive tumors and refractory disease do not have the same horizon. A proportionate choice must recognize both the possibility of benefit and the burden of treatment without applying one strategy to all malignant effusions.

Treatment, drainage, and prevention of recurrence

In tamponade image-guided pericardiocentesis is often the fastest means of decompression and sample acquisition. A surgical approach is considered when anatomy, loculations, bleeding, or other needs make it preferable. Circulatory support may be necessary as a bridge but does not remove compression. The procedure should be followed by reassessment of perfusion and echocardiography because mixed shock, ventricular dysfunction, or constriction may limit immediate recovery.

Prolonged drainage reduces the risk that a single evacuation will be followed quickly by reaccumulation. The 2025 ESC recommendations indicate extended drainage for several days, generally three to six, in suspected or confirmed neoplastic effusions. Catheter removal takes into account output, imaging, patency, and the clinical picture rather than the calendar alone. Minimal output may mean that the collection has emptied or that the catheter is obstructed; management should determine which situation is present before removal.

In the absence of compromise, the decision to drain depends on symptoms, size, course, and diagnostic need. A small stable effusion may be observed, whereas an enlarging or clinically relevant collection requires a more active strategy. Neoplastic suspicion increases the diagnostic value of sampling, particularly if the result changes treatment. It is inappropriate either to drain every minimal oncologic effusion automatically or to postpone intervention until shock when sound clinical or diagnostic indications exist.

Systemic antineoplastic therapy is an essential component when the disease is treatable and may reduce fluid production and recurrences. Selection depends on histologic type, biomarkers, and previous lines, not on a universal pericardial regimen. A surgical or thoracoscopic window may be useful in recurrences, while balloon pericardiotomy is an option in selected patients and experienced centers. Durable benefit, invasiveness, and the ability to continue cancer treatment must be compared in the individual case.

Intrapericardial treatment with cytotoxic or sclerosing agents may be considered to prevent recurrences in selected settings. Cisplatin has been used, among others, for involvement from lung carcinoma and thiotepa for breast carcinoma. Evidence comes from heterogeneous studies and case series and does not define a mandatory solution for everyone. Pain, arrhythmias, toxicity, and possible pericardial injury must be considered; the indication should be agreed upon by the oncologist and cardiologist and does not replace systemic disease control when possible.

Anti-inflammatory drugs may have a role for a symptomatic inflammatory component but do not treat infiltration or guarantee regression of a noninflammatory malignant effusion. Corticosteroids have different indications in immune-mediated toxicities and specific hematologic neoplasms; they are not universal empiric therapy for every oncologic effusion. Radiotherapy may be useful for radiosensitive tumors in selected situations, but the risk of further cardiac injury requires specialist assessment and prevents considering it a local intervention without consequences.

Prognosis, complications, and follow-up

Oncologic prognosis depends on histologic type, extent, response to treatment, and general condition. Pericardial involvement is often associated with advanced disease but does not allow a uniform individual prediction. Survival medians from case series may reflect tumors and treatments very different from those of the current patient. Communication should distinguish the immediate risk of compression, which is often treatable, from the course of the neoplasm and the likelihood of effusion recurrence.

Reaccumulation of fluid is an important complication and may require repeat drainage or a more durable procedure. Echocardiographic follow-up after catheter removal and during follow-up should be adapted to risk and course rather than using an identical schedule for everyone. New dyspnea does not automatically prove recurrence: pulmonary embolism, anemia, infection, and myocardial toxicity may cause the same symptoms. Surveillance must retain an etiologic approach even after a well-documented initial diagnosis.

Among procedural complications are bleeding, injury to adjacent structures, arrhythmias, and infection. Rarely, hemodynamic or respiratory deterioration may occur after decompression and requires prompt recognition. Serial assessment of blood pressure, oxygenation, and ventricular function is therefore important, particularly with large collections or limited cardiac reserve. Stability at the end of the procedure does not eliminate the need for surveillance over the following hours.

Constrictive physiology or effusive-constrictive physiology may maintain congestion after drainage and requires distinction from myocardial, valvular, or pulmonary injury. In infiltrative tumors, extensive surgery may not offer the same benefit as pericardiectomy for other causes. Indication and proportionality must be assessed in relation to anatomy, systemic disease, and goals. Persistent radiologic thickening without functional compromise does not by itself justify an invasive intervention.

Integrated surveillance coordinates cardiology, oncology, and pathology. Final cytology results, any molecular studies, and course after therapy should be shared because they may modify the initial interpretation. A collection labeled malignant solely on clinical grounds may require revision if discordant data emerge. Likewise, negative cytology does not close the pathway when progressive masses or other convincing elements justify targeted sampling.

Symptom control remains a goal even when the disease is not amenable to effective oncologic treatment. Procedure selection should consider expected relief, likelihood of reaccumulation, hospitalization time, and preferences. Palliative care may accompany active treatments and help define proportionate interventions. Success does not necessarily mean definitive absence of every effusion but prevention of compression and clinical benefit consistent with therapeutic possibilities and patient priorities.

References
1. Schulz-Menger J et al. 2025 ESC Guidelines for the management of myocarditis and pericarditis. European Heart Journal. 2025;46(40):3952-4041.
2. Klein AL et al. Pericardial Diseases: International Position Statement on New Concepts and Advances in Multimodality Cardiac Imaging. JACC: Cardiovascular Imaging. 2024;17(8):937-988.
3. Adler Y et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC). Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2015;36(42):2921-2964.
4. Mori S et al. Pericardial effusion in oncological patients: current knowledge and principles of management. Cardio-Oncology. 2024;10:8.
5. Lyon AR et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal. 2022;43(41):4229-4361.
6. Saab J et al. Diagnostic yield of cytopathology in evaluating pericardial effusions: Clinicopathologic analysis of 419 specimens. Cancer Cytopathology. 2017;125(2):128-137.
7. Roberts WC. Pericardial heart disease: its morphologic features and its causes. Proceedings (Baylor University Medical Center). 2005;18(1):38-55.
8. Spodick DH. Acute cardiac tamponade. New England Journal of Medicine. 2003;349(7):684-690.
9. Sagristà-Sauleda J et al. Effusive-constrictive pericarditis. New England Journal of Medicine. 2004;350(5):469-475.
10. Welch TD et al. Echocardiographic diagnosis of constrictive pericarditis: Mayo Clinic criteria. Circulation: Cardiovascular Imaging. 2014;7(3):526-534.
11. Imazio M et al. Risk of constrictive pericarditis after acute pericarditis. Circulation. 2011;124(11):1270-1275.